AbbVie Shares Hit All-Time High of 283.44 as SKYRIZI Crohn's Data and Sector Rally Drive Surge

AbbVie shares climbed to an all-time high of 283.44 on October 14, 2026, propelled by a broader healthcare sector rally that also lifted Eli Lilly and Merck, and by renewed investor focus on the immunology pipeline following positive data from the SKYRIZI subcutaneous Crohn's disease program. The move extended a roughly 24% year-to-date gain for the stock, which had closed the prior session at 274.36.

The catalyst from the immunology side centers on SKYRIZI's Phase 3 AFFIRM trial, which evaluated subcutaneous induction in adult patients with moderately to severely active Crohn's disease. The trial met its co-primary and ranked secondary endpoints at week 12, demonstrating superiority over placebo for SC-delivered induction. AbbVie submitted an FDA application for that subcutaneous indication in April 2026 and expects an approval decision later in 2026, a potential expansion that analysts say could meaningfully extend the drug's addressable market and shift the immunology investment narrative around the franchise.

AbbVie also announced a quarterly cash dividend of 1.73 per share with an ex-dividend date of October 15, 2026. Earnings are scheduled for October 30, 2026, which is the next key event investors are watching for guidance on Skyrizi and Rinvoq growth trajectories.